Clinical Trial Detail

NCT ID NCT03286530
Title Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

acute myeloid leukemia

Therapies

Ruxolitinib

Age Groups: senior adult

No variant requirements are available.